Antitumor efficacy, toxicity and pharmacokinetics of 9-nitrocamptothecin: role of lactone ratio

Author： Chen Jun   Hu Rong-Rong   Yang Xi-Xiong   Gu Wei   Tian Rong   Gong Fang   Luo Lei   Fang Fang   Chen Zhi-Peng   Cai Bao-Chang  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.72, Iss.4, 2013-10, pp. : 925-929

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors

By Yan Zhao   Zhu Zhongling   Li Kai   Chen Peng   Wang Liuchun   Huang Chun   Xue Jinhuai   Liu Meijun  

Cancer Chemotherapy and Pharmacology, Vol. 67, Iss. 4, 2011-04 ,pp. : 955-961

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma

By Konstadoulakis Manousos   Antonakis Pantelis   Tsibloulis Basil   Stathopoulos George   Manouras Andreas   Mylonaki Despoina   Golematis Basil  

Cancer Chemotherapy and Pharmacology, Vol. 48, Iss. 5, 2001-11 ,pp. : 417-420

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors

By Jung Laura   Ramanathan Ramesh   Egorin Merrill   Jin Ruzhi   Belani Chandra   Potter Douglas   Strychor Sandra   Trump Donald   Walko Christine   Fakih Marwan   Zamboni William  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 6, 2004-12 ,pp. : 487-496

Springer Publishing Company

Access to resources Recommend Favorite

PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression

By Muh Carrie   Joshi Shweta   Singh Alok   Kesari Santosh   Durden Donald   Makale Milan  

Journal of Neuro-Oncology, Vol. 116, Iss. 1, 2014-01 ,pp. : 89-97

Springer Publishing Company

Access to resources Recommend Favorite

Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme

By Raymond E.   Campone M.   Stupp R.   Menten J.   Chollet P.   Lesimple T.   Fety-Deporte R.   Lacombe D.   Paoletti X.   Fumoleau P.   for the EORTC Early Clinical Studies Group ECSG B.T.S.G..a.N.D.D.P..  

European Journal of Cancer, Vol. 38, Iss. 10, 2002-07 ,pp. : 1348-1350

Elsevier

Access to resources Recommend Favorite